NCT00139776

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of "Continuous Use" Of Celecoxib Vs. The "Usual Use" Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-inflammatory Medication for Control Of Their Pain

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 875 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.

Conditions

• Osteoarthritis, Knee
• Osteoarthritis, Hip

Interventions

Type	Name	Description
DRUG	Celecoxib	24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily. Placebo used as flare medication when directed.
DRUG	Celecoxib	24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.

Timeline

• Start date: 2005-07-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2005-08-31
• Last updated: 2021-03-29
• Results posted: 2009-05-19

Locations

124 sites across 8 countries: United States, Belgium, Brazil, Canada, Chile, Colombia, France, United Kingdom